Highlighted by Hong Kong DengYue Medicine What is Ensacove Ensartinib? Ensacove Ensartinib (X-396) is an advanced second-generation ALK tyrosine kinase inhibitor (TKI) designed to treat patients with ALK-positive non-small cell lung cancer (NSCLC). Developed to…
March 20, 2025 – A breakthrough in cancer treatment has emerged with the approval and introduction of Rezivertinib Mesylate Capsules, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to target EGFR-mutated…
May 6, 2020- The U.S. Food and Drug Administration (FDA) today approved Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring a jump mutation in exon 14 of…
August 5, 2023 – Eli Lilly and Company (Eli Lilly) announced that its RET inhibitor Retevmo (Selpercatinib) has achieved positive top-line data in a Phase III clinical trial for the treatment of patients with RET…
If you or a loved one has been prescribed Augtyro Repotrectinib for non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumors, you probably have a lot of questions. DengYue will explain these concerns in…
Pfizer Inc. recently announced that its third-generation anaplastic lymphoma kinase (ALK) inhibitor Lorviqua (generic name: Lorlatinib) has been approved by the European Commission As a monotherapy for the first-line treatment of adult patients with ALK-positive…
In a major breakthrough for precision oncology, Fulzerasib tablets have emerged as a promising treatment for patients with solid tumors harboring the KRAS G12C mutation. Developed by Innovent Biologics and GenFleet Therapeutics, Fulzerasib is an…
Garsorasib Company Today announced a significant milestone in the development of its flagship drug, Garsorasib, a novel KRAS G12C inhibitor designed to treat non-small cell lung cancer (NSCLC) and other solid tumors. This groundbreaking therapy has…
Taletrectinib Adipate Capsules have been approved by the China National Drug Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received prior ROS1…
Jazz Pharmaceuticals recently announced that its anticancer drug Zepzelca (Lurbinectedin Injection) in combination with Atezolizumab (Tecentriq) achieved significant overall survival (OS) and progression-free survival (PFS) improvements in the first-line maintenance treatment of extensive-stage small cell…
Guangzhou, China, October 15, 2023 – Ivonescimab Akeso (Kangfang Bio, HKEX: 9926.HK) today announced the latest clinical trial of its self-developed bispecific antibody drug Ivonescimab(R&D code: AK112). The drug has demonstrated significant anti-tumor activity in…
Introduction Lung cancer is one of the most common and serious types of cancer, but thanks to modern medicine, there have been significant advances in new medication for lung cancer over the past few years.…
